Pfizer On Reorganizing, M&A And Investing In Internal R&D

 
• By Jessica Merrill

The big pharma's leadership weighs in on why it made sense to organize biosimilars under innovative medicines, why it is investing more in internal R&D, and why tuck-in deals are more appealing than transformative M&A.

A pair of feet standing on a tarmac road with yellow arrow print pointing in three different directions for the concept of making decision at the crossroad.

More from Deals

More from Business